Long-Acting Cabotegravir and Rilpivirine in HIV-1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With HIV-1 Infection (ATLAS-2M), 48-Week Results: A Randomised, Multicentre, Open-Label, Phase 3b, Non-Inferiority Study
Lancet 2021 Dec 19;396(10267)1994-2005, ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, F Bredeek, M García Deltoro, S Swindells, JF Andrade-Villanueva, A Wong, MA Khuong-Josses, R Van Solingen-Ristea, V van Eygen, H Crauwels, S Ford, C Talarico, P Benn, Y Wang, KJ Hudson, V Chounta, A Cutrell, P Patel, M Shaefer, DA Margolis, KY Smith, S Vanveggel, W SpreenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.